Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib vs Sorafenib in Advanced HCC
NCT01232296Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of dovitinib in hepatocellular carcinoma (HCC), sponsored by Novartis. Started Jul 2011; status: completed.
02
Drugs
dovitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01232296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232296.